Form 4: Oragenics Inc. Director Robert Koski Acquires Options

Director Robert Koski acquired options to purchase 65,000 shares of Oragenics Inc. common stock on September 19, 2024.

Summary

• Robert Koski, a director of Oragenics Inc., acquired options to purchase 65,000 shares of the company's common stock on September 19, 2024.
• The options were granted under the company's 2021 Equity Incentive Plan as part of the non-employee director compensation program.
• The exercise price of the options is $0.48, which is the closing price of the company's stock on the grant date.
• The options vest immediately and expire on September 19, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction related to director compensation.

Positives

• The immediate vesting of the options could incentivize the director to work towards increasing shareholder value.

Industry Context

This is a standard practice for compensating non-employee directors, aligning their interests with those of the shareholders.

Comparison to Industry Standards

• Granting stock options to directors is a common practice among publicly traded companies to align their interests with shareholders.
• The vesting schedule and exercise price are typical for such grants.

Stakeholder Impact

• The option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates

Keywords

Oragenics Inc., Director, Robert Koski, Options, Equity Incentive Plan, Beneficial Ownership, OGEN